CA3224537C — Use of migalastat in the treatment of fabry patients having renal impairment
Assigned to Amicus Therapeutics Inc · Expires 2025-09-09 · 1y expired
What this patent protects
Treatment methods for Fabry disease in patients with renal impairment and/or high proteinuria include administering approximately 100 to 150 mg of a free-form equivalent of migalastat or a related salt every other day. Some methods also aim to stabilize renal function, reduce lef…
USPTO Abstract
Treatment methods for Fabry disease in patients with renal impairment and/or high proteinuria include administering approximately 100 to 150 mg of a free-form equivalent of migalastat or a related salt every other day. Some methods also aim to stabilize renal function, reduce left ventricular mass index, lower plasma globotriaosylsphingosine levels, and/or increase α-galactosidase A activity in the patient.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.